Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?

To: Johnny Canuck who wrote (36451)	3/15/2002 1:44:18 PM
From: Johnny Canuck	Read Replies (1) \| Respond to of 68124

Applied Films (AFCO) 27.75 +0.75: After a two-day slide which took AFCO's stock price from about $34 to $27, the stock is staging a recovery today, gaining 2.8%. Aiding in AFCO's rebound is Needham & Co's reiteration of Buy rating and price target of $35 as firm believes sharp selloff is overdone. Although firm believes AFCO has yet to see a pickup in orders from Taiwanese manufacturers planning Gen 5 LCD lines, firm continues to expect significant capacity additions over the next 2 years as industry capacity continues to tighten, demand remains strong and panel prices are rising; thinks AFCO represents attractive valuation for a capital equipment company focused on the fast-growing FPD market. ZOLL Medical (ZOLL) 32.45 -2.35: Yesterday, Zoll, maker of non-invasive cardiac resuscitation devices, announced that it won a contract with Broadlane, a group purchasing organization, to provide cardiac resuscitation equipment to its membership. Also, ZOLL issued a press release giving an update on its public access defibrillation (PAD) product. Although company still expects approval this month based on recent contacts with the FDA, it expects no PAD revenues this quarter and may not be able to make up the shortfall with non-PAD revenues... This morning, Pacific Growth Equities reiterates Market Perform on ZOLL. In model, firm currently estimates just over $1 mln in PAD revenues this quarter and will likely be taking that out; says negative impact would be approximately 3 cents in the March Q... Stock taking a hit today, losing 6.8%. FreeMarkets (FMKT) 24.82 -0.25: This morning, Pacific Crest initiated coverage with a Buy rating and price target of $32. Firm says FMKT's key asset and competitive advantage is the human powered aspect of its business, which sources and qualifies vendors for its online market making activities. Through new customers and increased purchasing from existing customers, firm thinks FMKT can continue to grow revenue 30% annually over next several years. As FMKT drives from its first quarter of profitability to firm's target operating margin of 30%, believes that it can grow earnings at a 3-5 year CAGR of 40-50%... Stock not responding to these upbeat comments as it trades down 1%.